Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
inx-08189 + ribavirin
- Development stage
- Preclinical
- Lead developer
- Bristol Myers Squibb
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
INX-08189 + ribavirin is an experimental antiviral drug combination developed primarily for the treatment of chronic hepatitis C virus (HCV) infection and studied preclinically for other RNA viruses. INX-08189 is a phosphoramidate prodrug of 6-O-methyl-2'-C-methyl guanosine, acting as a nucleotide analog inhibitor of the HCV NS5b RNA-dependent RNA polymerase. Ribavirin is a guanosine analog with multiple antiviral mechanisms, including direct inhibition of viral polymerases and induction of error-prone viral replication. The combination demonstrates strong synergistic antiviral activity both in vitro and in clinical trials, likely due to complementary inhibition of viral replication and enhanced suppression of resistance mutations. Clinical development focused on interferon-free regimens, but development was discontinued before regulatory approval due to safety concerns with INX-08189.
- Other names
- INX-08189 + ribavirininx-189 + ribavirin
02
Targets
NS5B (Hepatitis C virus non-structural protein 5B (NS5B) RNA-dependent RNA polymerase)
Beyond the preview
Go deeper on inx-08189 + ribavirin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on inx-08189 + ribavirin.